Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system

Objective: To investigate and analyze the post-marketing adverse event (AE) data of multiple sclerosis (MS) therapeutic drug dalfampridine using the US Food and Drug Administration Adverse Event Reporting System (FAERS) for its clinical safety application. Methods: Use OpenVigil2.1 platform to obtai...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Rui, Lei, Jing, Pan, Sicen, Zhang, Hong, Tong, Yongtao, Wu, Wei, Huang, Yi, Lai, Xiaodan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538962/
https://www.ncbi.nlm.nih.gov/pubmed/37781705
http://dx.doi.org/10.3389/fphar.2023.1226086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538962/
https://www.ncbi.nlm.nih.gov/pubmed/37781705
http://dx.doi.org/10.3389/fphar.2023.1226086

Ejemplares similares